Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.

ABSTRACT:

Aims

To confirm superiority on glycaemic control by switching from sitagliptin to liraglutide 1.8?mg/d versus continued sitagliptin.

Materials and methods

A randomized, multicentre, double-blind, double-dummy, active-controlled trial across 86 office- or hospital-based sites in North America, Europe and Asia. Subjects with type 2 diabetes who had inadequate glycaemic control (glycated haemoglobin [HbA1c] 7.5-9.5% on sitagliptin (100?mg/d) and metformin (?1500?mg daily) for ?90?days were randomized to either switch to liraglutide (n?=?203) or continue sitagliptin (n?=?204), both with metformin. The primary endpoint was change in HbA1c from baseline to week 26. Change in body weight was a confirmatory secondary endpoint.

Results

Greater reduction in mean HbA1c was achieved with liraglutide than with continued sitagliptin [-1.14% vs. -0.54%; estimated mean treatment difference (ETD): -0.61% (95% CI -0.82 to -0.40; p?ConclusionsSubjects insufficiently controlled with sitagliptin who switch to liraglutide can obtain clinically relevant reductions in glycaemia and body weight, without compromising safety. A switch from sitagliptin to liraglutide provides an option for improved management of type 2 diabetes while still allowing patients to remain on dual therapy.

SUBMITTER: Bailey TS 

PROVIDER: S-EPMC5129465 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature